CARLOS ALBERTO BUCHPIGUEL
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Radiologia, Faculdade de Medicina - Docente
LIM/43 - Laboratório de Medicina Nuclear, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/43 - Laboratório de Medicina Nuclear, Hospital das Clínicas, Faculdade de Medicina - Líder
9 resultados
Resultados de Busca
Agora exibindo 1 - 9 de 9
conferenceObject Case study: Evaluating the new University of Florida hybrid pediatric phantoms and tissue weighting factors from ICRP Publication 103 for diagnostic dosimetry(2018) JOSEFSSON, Anders; HOBBS, Robert; RANKA, Sagar; SCHWARZ, Bryan; CARVALHO, Jose Willegaignon de Amorim de; BUCHPIGUEL, Carlos Alberto; SAPIENZA, Marcelo Tatit; BOLCH, Wesley; SGOUROS, GeorgeconferenceObject The Value of Brain FDG-PET or SPECT in predicting the clinical features of Corticobasal Syndrome(2018) PARMERA, Jacy; ARANHA, Mateus; COUTINHO, Artur; STUDART, Adalberto; ONO, Carla; NITRINI, Ricardo; BUCHPIGUEL, Carlos; BRUCKI, SoniaconferenceObject BRAIN METABOLIC IMAGING PATTERNS IN DIFFERENT AUTOANTIBODY-MEDIATED ENCEPHALITIS: A SERIES OF 10 CASES(2016) COUTINHO, Artur; SORIANO, Marianne; SIMABUKURO, Mateus; NUNES, Rafael; ONO, Carla; CASTRO, Luis; BUCHPIGUEL, CarlosconferenceObject Is the early phase (CPIB)-C-11 PET imaging similar to (18)FFDG PET imaging in normal elderly and Alzheimer's disease(2018) CARNEIRO, Camila; COUTINHO, Artur; DURAN, Fabio; ONO, Carla; GARCEZ, Alexandre; PICOLO, Douglas; BUSATTO, Geraldo; FARIA, Daniele; BUCHPIGUEL, CarlosconferenceObject The receiver operating characteristic (ROC) curve for classification of 18F-NaF uptake on PET/CT(2012) DUARTE, Paulo; COURA FILHO, George; LIMA, Marcos; ONO, Carla; SADO, Heitor; CARVALHO, Giovanna; SAPIENZA, Marcelo; BUCHPIGUEL, CarlosconferenceObject Correlations between [18F]FDG-PET and Naa/mI spectroscopy data of the posterior cingulate cortex in amnestic mild cognitive impairment and Alzheimer's disease.(2016) COUTINHO, Artur; PORTO, Fabio; ZAMPIERI, Poliana; OTADUY, Maria; NUNES, Rafael; PERROCO, Tibor; BOTTINO, Cassio; ONO, Carla; LEITE, Claudia; BUCHPIGUEL, Carlos- Comparative Dosimetry for Ga-68-DOTATATE: Impact of Using Updated ICRP Phantoms, S Values, and Tissue-Weighting Factors(2018) JOSEFSSON, Anders; HOBBS, Robert F.; RANKA, Sagar; SCHWARZ, Bryan C.; PLYKU, Donika; CARVALHO, Jose Willegaignon de Amorim de; BUCHPIGUEL, Carlos Alberto; SAPIENZA, Marcelo Tatit; BOLCH, Wesley E.; SGOUROS, GeorgeThe data that have been used in almost all calculations of MIRD S value absorbed dose and effective dose are based on stylized anatomic computational phantoms and tissue-weighting factors adopted by the International Commission on Radiological Protection (ICRP) in its publication 60. The more anatomically realistic phantoms that have recently become available are likely to provide more accurate effective doses for diagnostic agents. Ga-68-DOTATATE is a radiolabeled somatostatin analog that binds with high affinity to somatostatin receptors, which are overexpressed in neuroendocrine tumors and can be used for diagnostic PET/CT-based imaging. Several studies have reported effective doses for Ga-68-DOTATATE using the stylized Cristy-Eckerman (CE) phantoms from 1987; here, we present effective dose calculations using both the ICRP 60 and more updated formalisms. Methods: Whole-body PET/CT scans were acquired for 16 patients after Ga-68-DOTATATE administration. Contours were drawn on the CT images for spleen, liver, kidneys, adrenal glands, brain, heart, lungs, thyroid gland, salivary glands, testes, red marrow (L1-L5), muscle (right thigh), and whole body. Dosimetric calculations were based on the CE phantoms and the more recent ICRP 110 reference-voxel phantoms. Tissue-weighting factors from ICRP 60 and ICRP 103 were used in effective dose calculations for the CE phantoms and ICRP 110 phantoms, respectively. Results: The highest absorbed dose coefficients (absorbed dose per unit activity) were, in descending order, in the spleen, pituitary gland, kidneys, adrenal glands, and liver. For ICRP 110 phantoms with tissue-weighting factors from ICRP 103, the effective dose coefficient was 0.023 +/- 0.003 mSv/MBq, which was significantly lower than the 0.027 +/- 0.005 mSv/MBq calculated for CE phantoms with tissue-weighting factors from ICRP 60. One of the largest differences in estimated absorbed dose coefficients was for the urinary bladder wall, at 0.040 +/- 0.011 mGy/MBq for ICRP 110 phantoms compared with 0.090 +/- 0.032 mGy/MBq for CE phantoms. Conclusion: This study showed that the effective dose coefficient was slightly overestimated for CE phantoms, compared with ICRP 110 phantoms using the latest tissue-weighting factors from ICRP 103. The more detailed handling of electron transport in the latest phantom calculations gives significant differences in estimates of the absorbed dose to stem cells in the walled organs of the alimentary tract.
conferenceObject Comparison of standardized uptake value (SUV) measured on 18F-NaF PET/CT using three different values of tube current intensity (mAs) on CT(2012) DUARTE, Paulo; COURA FILHO, Geore; LIMA, Marcos; ONO, Carla; SADO, Heitor; CARVALHO, Giovanna; SAPIENZA, Marcelo; BUCHPIGUEL, Carlos- PET Imaging of Disease Progression and Treatment Effects in the Experimental Autoimmune Encephalomyelitis Rat Model(2014) FARIA, Daniele de Paula; VLAMING, Maria L. H.; COPRAY, Sjef C. V. M.; TIELEN, Frans; ANTHONIJSZ, Herma J. A.; SIJBESMA, Jurgen W. A.; BUCHPIGUEL, Carlos A.; DIERCKX, Rudi A. J. O.; HOORN, Jose W. A. van der; VRIES, Erik F. J. deThe experimental autoimmune encephalomyelitis model is a model of multiple sclerosis that closely mimics the disease characteristics in humans. The main hallmarks of multiple sclerosis are neuroinflammation (microglia activation, monocyte invasion, and T-cell infiltration) and demyelination. PET imaging may be a useful non-invasive technique for monitoring disease progression and drug treatment efficacy in vivo. Methods: Experimental autoimmune encephalomyelitis was induced by myelin-oligodendrocyte glycoprotein immunization in female Dark Agouti rats. Experimental autoimmune encephalomyelitis rats were imaged at baseline and at days 6, 11, 15, and 19 after immunization to monitor monocyte and microglia activation (C-11-PK11195) and demyelination (C-11-MeDAS) during normal disease progression and during treatment with dexamethasone. Results: C-11-PK11195 PET detected activation of microglia and monocytes in the brain stem and spinal cord during disease progression. The uptake of C-11-PK11195 was elevated in dexamethasone-treated animals that had shown mild clinical symptoms that had resolved at the time of imaging. Demyelination was not detected by C-11-MeDAS PET, probably because of the small size of the lesions (average, 0.13 mm). Conclusion: PET imaging of neuroinflammation can be used to monitor disease progression and the consequences of treatment in the experimental autoimmune encephalomyelitis rat model. PET imaging was more sensitive than clinical symptoms for detecting inflammatory changes in the central nervous system.